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Previous in-vitro studies on anabolic androgenic steroids (AAS) were 
performed by other horseracing clubs around the world. The studies 
demonstrated the extensive metabolism of hydrophobic designer steroids in 
the horse liver suggesting the fast elimination of the parent drug in-vivo. 
Hence, there is a potential challenge in detecting selected parent drug during 
targeted screening and further raises the pertinent question of whether some of 
the metabolites of AAS are pharmacologically active. It is therefore important 
to determine the appropriate analytes to monitor, like parent drug, metabolites 
or both. Due to ethical issues related to animal research, alternative approaches 
have to be used to study the metabolic stability and metabolite identification of 
AAS. There is also the constant challenge of detecting new AAS abuse in 
equine sports. 
 
Our present study was designed to investigate both the non-targeted and 
targeted metabolic profiling approaches to bridge the gaps in the detection of 
doping agents. In-vitro experiments were carried out using horse liver 
microsomes to understand the metabolic stability and identify the metabolites 
of ethylestrenol, metribolone, ecdysone and 20-hydroxy ecdysone. Global 







Ethylestrenol is a short acting AAS with progesterone-like activity and little 
androgenic activity. Ethylestrenol has been studied in-vivo in equine studies. 
In addition, in-vitro models in cattle and rats have also been investigated. 
From the small-scale synthesis experiment, it is clear that the unknown 
metabolite generated in horse liver microsomes is possibly associated with 
17α-ethyl-5α-estrane-3β,17β diol. With the possible structure of the 
metabolite, large-scale synthesis experiments could be conducted and the 
product can be characterized. This metabolite could be explored as an analyte 
to be monitored in ethylestrenol abuse. 
 
Metribolone is a potent synthetic AAS reported since the late 1960s. Androgen 
binding assays were done on metribolone and it was found to have high 
affinity for androgen receptors. However it was never marketed as an AAS 
due to its high liver toxicity. Information on metribolone metabolism is 
limited. Our data showed that metribolone metabolizes in horse liver 
microsomes to produce multiple metabolites. The major metabolite was 
elucidated to be 16-hydroxy metribolone. 16-hydroxy metribolone could be 
explored as an analyte to be monitored in metribolone abuse.  
 
Ecdysone and 20-hydroxyecdysone are ecdysteroids which are insect-molting 
hormones present in various arthropods and plants. Their structures are related 
to cholesterol. They are known to increase protein synthesis upon 
administration. In addition, studies on 20-hydroxyecdysone have shown that it 





synthetic AAS. Ecdysteroid metabolism was previously studied in humans. 
Our data showed that there is no significant metabolism of ecdysone and 20-
hydroxy ecdysone in horse liver microsomes and suggested that it might be 
more appropriate to monitor the parent drug in dope testing.   
  
Global profiling of equine plasma obtained from horses of different genders 
was performed in the current study. As the chemometric models were not 
sufficiently robust, the results were not conclusive in differentiating the 
different genders of the horses. Nevertheless, the broad classification trends 
suggested that there might be unique metabotype associated with each gender. 
Further studies need to be performed to determine the baseline metabotype of 
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Horse racing was first introduced in the Olympics in 680 BC in the form of 
chariot racing [1].  Even as early as the Roman times (10th century BC), 
humans embarked on the quest  to improve the performance of race horses [2]. 
The Romans used an innocuous mix of water and honey called “hydromel” 
which was believed to rejuvenate race horses. The quest for good stamina and 
speed of the race horses led to the breeding of the Thoroughbreds in the 1700s 
[2]. Thoroughbreds are a distinct breed of horses that are derived from a single 
breed line. They are also known as purebreds and the intense selection criteria 
make the Thoroughbreds highly adapted athletes, known for their agility and 
speed. Today, horse racing is a billion-dollar industry where trainers and 
owners are motivated by the prize-money to overcome obstacles to win races. 
This has led to trainers and owners using unorthodox methods such as 
prohibited substances to give their horses an unfair advantage in racing.  
 
There are generally four scenarios of doping horses with prohibited 





the speed of horses in racing. The second scenario is the administration of 
tranquilizers or depressant drugs to suppress the performance of competitors’ 
horses. This class of drugs is also called “stoppers”. The third scenario is the 
restoration of the normal performance of horses port-trauma such as surgery. 
The fourth scenario is accidental doping of horses with food, plant or 
contaminants that give rise to a positive result.     
 
1.1.2 List of prohibited substances 
 
The prohibited substance list is a guideline that stipulates forbidden drugs in 
horse racing competition. The list of prohibited substances varies according to 
different horse racing nations. For example, in United States of America 
(U.S.A.), phenylbutazone and furosemide are allowed in many states but they 
are banned in British racing [3]. The list consists of different classes of 
prohibited substances like stimulants, anti-pyretics, analgesics, diuretics, anti-
inflammatory substances, antihistamines, local anaesthetics, muscle relaxants, 
respiratory stimulants, sex hormones, anabolic agents, corticosteroids and 
substances affecting blood coagulation. Stimulants like amphetamine, 
methamphetamine, caffeine, ephedrine and methylphenidate are known to 
have neurological effect on the race horses thereby increasing the their 
running ability [2]. This is primarily due to the pharmacological effects of the 
stimulants in increasing the alertness and decreasing fatigue of horses.  





theobromine make a good compliment for aspirin. The increased rate of 
urination can eliminate aspirin from the system at a faster rate than in the 
absence of a diuretic [2]. This would evade the detection of aspirin. Cocaine is 
another drug of abuse because of its stimulant and local anesthetic effects. 
Narcotic analgesics like fentanyl and morphine depress pain and increase the 
running pace of horses but lead to respiratory depression. Cimetidine, a H2 
antagonist, is used for treatment of stomach ulcers and acid reflux, common 
amongst race horses. The overall aim in using the prohibited substances is to 
improve the performance of the race horses during competition. 
 
Doping involves good knowledge of each horse and its response when the 
drug is administered. Therefore doping of horses is usually secretly performed 
by trainers or employers. The dose of the drug is critical as too little would not 
elicit the desired effect while too much could kill the horse. Another important 
consideration is the timing of the dosing, too early could render the horse 
uncontrollable in the parade ring and lead to disqualification from the race. A 
dose administration given too late could lead to a delayed effect and minimal 
impact on the race outcome.   
 
The use of prohibited substances discourages clean athletes, disillusions 
punters, causes unjust monetary loss to horse owners and affects the equine 
breeding industry. In the breeding industry, selection of horses is based on 





masked by the use of performance enhancing substances therefore affecting 
the new breed.  
 
The aim of the Singapore Turf Club is therefore to create a level playing field 
and discourage doping in equine racing. This is achieved through extensive 
pre-race and post-race testing of doped substances using both equine plasma 
and urine samples. 
 
1.1.3 Current screening methods 
 
The first case of doping was reported in England in 1666. Racing analyst at 
that time did not have analytical techniques to identify the exact dopant. In 
1910, Russian chemist, Bukowski demonstrated that drugs could be detected 
in horse saliva but the analytical method was not revealed [2]. Even now, with 
modern analytical technologies, dope testing in equine racing is still closely 
guided and not publicly published.  
 
The science of dope testing needs to be specific, sensitive and highly accurate 
in order to generate reliable data to differentiate between doped and un-doped 
horses. Analytical instruments used for this purpose usually consist of 
chromatographic separation techniques coupled to mass analyzers such as 
liquid chromatography coupled to tandem mass spectrometry (LC/MS/MS) 





monitoring (SIM) and selected reaction monitoring (SRM) are the common 
scanning modes used in these analytical techniques. Modern ion monitoring 
was introduced by Sweeley et al. They developed a technique where multiple 
selected ions are monitored through the MS [4]. In SIM scan mode, a single, 
most abundant (base ion), ion of a specific compound is selected and 
monitored. This increases the sensitivity of the specific selected ion. SRM, 
also known as multiple reaction monitoring (MRM), is usually applicable with 
triple quadrupole mass spectrometer (Figure 1). In SRM mode, parent ions are 
selected in the first quadrupole (Q1) and fragmented by the collision cell (Q2 
in Figure 1). This generates product ions which are analyzed via the third 
quadrupole (Q3) [5].  
 
The main advantage of these scanning modes over full scan experiments is the 
enhanced sensitivity and selectivity as the parent-product ion pair is typically 










For example, screening, quantification and confirmation of boldenone, 
nandrolone, stanozolol, normethanrolone, testosterone and trenbolone were 
performed in the SRM mode using the triple quadrupole mass analyzer where 
both parent and product ions were monitored sequentially [7]. Another 
example is capillary-zone electrophoresis (CZE) used in the separation and 
identification of β-adrenoceptor agents by monitoring parent ions in the SIM 
mode [8]. In GC/MS, fluoxymesterone metabolite in equine urine was 
quantitated in SIM mode [9]. Doping control analysis of recombinant human 
erythropoietin (rhEPO) and its synthetic analogues in equine plasma were 
analyzed using nano-LC/MS/MS [10]. The main disadvantage of utilizing 
these selective scanning modes is that the targeted monitoring of analytes 
leaves a void in the testing of unknown analytes.  
  





Steroids belong to an important class of prohibited substances. The first 
androgenic steroid, androsterone, was isolated in male bovine urine by 
Butenandt in the 1930s [11]. Later, Kochakian et al. demonstrated that the 





steroids (AAS) are synthetic derivatives of testosterone. Testosterone is a male 
hormone known to promote muscle growth and was isolated by Laqueur in 
1935 [13]. Testosterone is ten times more potent than androsterone. After the 
isolation of testosterone, research groups produced numerous analogs of 
testosterone in the next decade. In 1958, Dr Munson concluded that 5α-
androstanes and 3-ketosteroids were more active than 5β-isomers and 3β-
hydroxysteroids respectively. The introduction of a methyl functional group in 
the 17α-position also increased androgenic potency [13].     
 
Although AAS have therapeutic values like treatment of cancer and AIDS, 
they are also used as illicit drugs in human and animal sports. For example, the 
synthetic AAS, stanazolol, effectively reduces the frequency of hereditary 
angioedema attacks [14]. Stanozolol is known to increase muscle mass in 
animals and can be used in human as well. Thus, the use of AAS is prohibited 
in human and animal sports.  
 
The androgen part of AAS contributes to the masculinity factor and the 
anabolic part contributes to cell growth. The abuse of AAS is primarily due to 
the anabolic effect. Thus new illicit AAS are usually of higher anabolic 
activity but relatively weaker androgenic activities. The effects of AAS are 
produced by their binding to specific biological receptors where the binding 






1.2.2  Mechanism of action 
 
Each AAS binds to receptors within the cytoplasm of muscle cells of skeletal 
muscle tissue. Consequently, it reduces fat by increasing basal metabolic rate 
thereby increasing muscle mass. The process of protein synthesis within the 
muscle cells begins with the steroid/receptor complex entering the muscle cell 
nucleus. This stimulates protein synthesis resulting in muscle growth. 
Combination of athletic and weight training alone is deemed insufficient, so 
prolonged protein synthesis is induced for enhanced muscle mass, strength, 
stamina and endurance. Each AAS also stimulates muscle growth and 
increases muscle strength through reduction of protein catabolism, production 
of cytokines like IGF-1 and increase in androgen receptors. Administration of 
AAS should, theoretically, restore the balance between anabolic and catabolic 
hormones, therefore influencing recovery post-exercise [15]. 
 
In the bone tissue, the osteoblast is stimulated when the steroid binds to its 
receptors. This stimulation incorporates calcium and other proteins to form 
new bone tissue which increases bone mineral density and strength of bones. 
In the red blood cells, the binding of steroid to receptor results in an elevated 
haemoglobin concentration. The steroid/receptor complex together with EPO 










































In human sports, AAS are proven  to be effective, combined with exercise and 
proper diet [18]. In equine sports, AAS gives the horse an overall feeling of 
well-being, confidence, alertness, aggression and good appetite. It was 
demonstrated that AAS exert significant effects  on mares, female horses, 
geldings and castrated horses [15]. However, AAS, when used extensively, 
have adverse effects like liver damage [15]. The use of AAS can also outstrip 
the strength of tendons and lead to its rupture in steroid users [19]. 
 
The two most commonly used steroids in equine sports are boldenone and 
stanazolol (Figure 3). These two steroids are known to increase protein 
synthesis in the body, as such leading to muscle and weight gain. The overall 
concern of integrity and safety in equine racing has forced some states, Iowa 














Figure 3: Structures of (1) boldenone and (2) stanazolol. 
 
Hence it is paramount to discourage doping of AAS in horses by developing 





One area that is currently of concern in equine and human anti-doping control 
is the use of so-called “designer drugs”. These compounds are synthesized to 
circumvent current analytical screening methods by introducing small 
structural changes that will render commonly used mass spectrometry-based 
screening methods ineffective. 
 
Majority of designer drugs were once in the drug development pipeline of 
pharmaceutical companies but were not progressed to late development stage 
due to toxicological issues or poor pharmacokinetic characteristics. The other 
source of designer AAS is the black market where they are produced illicitly 
and their identity and purity cannot be determined. Almost always, the 
designer drugs are channelled from human to equine sports. 
  
1.2.3 Challenges in detection of anabolic androgenic steroids  
 
Anabolic steroids share a core structure (Figure 4), and minor chemical 
modification to one of the four rings of a known androgen can be used to 
produce a novel compound. This potential for structural modifications renders 
AAS a good designer drug scaffold. However, to be effective, the derivative 
must still retain the important pharmacological properties of the anabolic 
agents and this means that the binding to the androgen receptor must not be 
compromised by the structural modification. This limits the amount of 





pharmacologically inactive. If organic chemists successfully synthesize 
designer AAS, it would be undetectable with present libraries due to their 









































Figure 4: Chemical structure of AAS. 
 
An example of a designer AAS is tetrahydrogestrinone (THG) which was first 
reported in 2003 [21]. THG is an illicit steroid that has potent androgenic and 
anabolic effects. THG is structurally similar to gestrinone, which is a 
prohibited steroid (Figure 5). The detection of this AAS was hindered by its 
poor behaviour under GC/MS conditions. Its poor behaviour was attributed to 
the production of multiple isomeric trimethylsilyl derivatives and its presence 
in trace amounts in urine samples. Therefore, it was found to be more suitable 
for LC-MS conditions [21]. This case is an example of the difficulty in 






Current detection methods employed a targeted approach, using SIM and 
SRM, to scout for only compounds in the prohibited substance list or 
compounds that are well characterized. These are the limitations of the current 
detection methods. As such, designer drugs would escape detection by the 
available analytical methods due to their chemical modifications. For example, 
norbolethone, a designer steroid (Figure 5), could not be detected using the 
current detection methods. However, analytical chemists observed no 
detectable level of endogenous steroids in urine from female athletes. It was 
eventually demonstrated that norbolethone was suppressing the steroid profile 
[22].  Norbolethone was developed by Wyeth Pharmaceuticals in the early 
1950s but was never brought to the market because it was more anabolic than 
its methyl isomer.  
 
Since there is an unknown difference in metabolism between human and 
horse, the direct extrapolation of the human data to horse is unrealistic. Hence 





















Figure 5: Structures of (1) THG, (2) gestrinone and (3) norbolethone. 
 
With the ever-increasing list of designer AAS being synthesized and abused, 
testing laboratories have to constantly develop new analytical methods and 
strategies to detect dopers. Steroids such as ecdysone and 20-hydroxyecdysone 
are ecdysteroids which are insect-molting hormones present in various 
arthropods and plants. Their structures are related to cholesterol (Figure 6).  
They are known to increase protein synthesis upon administration [23, 24]. In 
addition, studies on 20-hydroxyecdysone have shown that it is capable of 
enhancing muscle growth without the negative effects of synthetic AAS [24]. 







































Figure 6: Structures of (1) ecdysone, (2) 20-hydroxy ecdysone and (3) 
cholesterol. 
 
Ethylestrenol (Figure 7) is a short acting AAS with progesterone-like activity 
and little androgenic activity. Ethylestrenol have been studied in equine via in-
vivo studies [25, 26]. In addition, in-vitro models (liver microsomes) of cattle 
and rats have also been investigated [27, 28].  
 
Metribolone (Figure 7) is a potent synthetic AAS which was reported in the 
late 1960s. Androgen binding assays were done on metribolone and it was 
found to have high affinity for androgen receptors [29, 30]. However it was 
never marketed as an AAS due to its high liver toxicity [31]. Information on 
metribolone metabolism is limited.   
 
These steroids have potential for abuse in equine racing. To date, only limited 
pharmacokinetics studies have been done in equine model. Previous works on 





world [32-34]. The studies demonstrated the extensive metabolism of 
hydrophobic designer steroids in the horse liver suggesting the fast elimination 
of the parent drug in-vivo. Hence, there is a challenge in detecting the parent 
drug during targeted screening and further raises the pertinent question of 
whether some of the metabolites of AAS are pharmacologically active. It is 
therefore important to determine the appropriate analytes to monitor, such as 















1.3.1 Background  
 
Metabonomics is the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological 
stimuli, generic modification and pharmacological intervention [35]. This was 





using chemometrics techniques. The term metabonomics was coined in the 
1990s but the technique was already in use since the 1980s [35]. 
Metabonomics have been used in the study of drug toxicity, animal models 
and description mechanisms [36, 37]. It was also used to study organisms and 
plants, diagnose diseases and elucidate gene function [37-40]. Metabonomics 
has also been used to study traditional Chinese medicine (TCM) safety studies 
and drug metabolism [41, 42].  The human diseases involve interaction 
between multiple gene processes and environmental factors. To better 
understand such disease mechanism, advanced analytical techniques are used 
to generate new molecular information to complement information from 
genomics and transcriptomics. Transcripts and proteins can be identified from 
their genomic information but the molecular identity of molecules need 
sophisticated instrumentation like GC/MS, LC/MS, capillary electrophoresis 
(CE/MS), nuclear magnetic resonance (NMR) spectroscopy, laser induced 
fluorescence (LIF) detection and Raman and Fourier transform infrared ( FT-
IR) approaches [35, 43, 44]. The large amount of data generated by these 
techniques make it difficult to interpret the information. Genomics and 
proteomics do not reflect the "final outcomes" of the phenotypes whereas 
metabonomics is the direct reflection of the organism’s phenotypes [45, 46]. 







The high quality of data shows the temporal state of the organism through 
their endogenous metabolites. These data can be interpreted in two ways, 
metabolic fingerprinting and metabolic profiling [44]. In metabolic 
fingerprinting, the data is a numerical representation of the biological systems 
without any identity of the actual metabolites. For example the acquisitions of 
NMR or MS spectra act as a fingerprint of the metabolites of the investigated 
biological system. This is done in the absence of the metabolites’ identities 
[45]. Such data can be analyzed through multivariate statistical analysis. 
Global metabolic profiling is also known as metabonomics or metabolomics 
depending on the nature and scope of scientific investigation. Metabolic 
profiling provides mechanistic information on perturbed metabolic pathways 
and the associated biomarkers. This is targeted and usually quantitative 
analysis of a specific group of metabolites like amino acids [45]. Data analysis 
in metabolic profiling involves supervised and unsupervised multivariate 
chemometrics statistics. The unsupervised principal component analysis 
(PCA) is used to study the classification trends associated with the test groups 
(e.g. different types of race horses) and identify outliers (e.g. horse suffering 
from an unknown disease). Supervised partial-least squares-discriminant 
analysis (PLS-DA) generates a predictive model that identifies the marker 







1.3.2  Current uses in profiling diseases and doping 
 
Metabonomics, a global non-targeted metabolic profiling approach, has been 
explored to study different biological systems. For example, stress in rat 
models have been studied by Wang at el. using metabonomics [47]. Stress 
was induced by forced swimming for 5 min, at 40⁰C for 5 min, water 
deprivation for 24 h, food deprivation for 24 h, tail squeezing for 1 min, 
electric shock for 10 s, reversal of day and night, exposure to -10⁰C for 30 
min and 2 h behaviour restriction. Urine samples were collected from the 
experimental rats and analyzed by GC/MS. The complex GC/MS data 
obtained were analyzed using multivariate statistical analysis. The results 
demonstrated that stress affected some of the biochemical pathways which 
gradually recovered when the stressor was withdrawn. If the stress continued, 
biological pathways like tyrosine, tryptophan and glutamine pathways were 
progressively affected leading to depression-like state. Similar experiments 
with equine plasma samples can also be done using GC/TOFMS. The 
introduction of exogenous substance could also indicate changes in the 
biochemical pathways.  
 
As shown in previous human studies, metabonomics can be used to monitor 
the changes in the endogenous metabolites for indication of diseases and 
genetic disorders [48-55]. For example in the study of differentiating children 





current diagnosis involves observation by a trained clinician and this is 
subjective. The authors did metabolic profiling using NMR/MS. They found 
that urinary amino acids glutamate and taurine were perturbed in autistic 
individuals compared to their controls. Preliminary findings show that urinary 
metabolites hippurate, N-methyl nicotinic acid and N-methyl nicotinamide and 
taurine could be possible biomarkers. This shows that even though the 
children are from the same families as the respective controls, there are still 
changes in the metabolic profiles. This might also be true in the case of race 
horses whose genetics is well-conserved but there may still be some metabolic 
differences. 
 
Metabonomics has also been used to differentiate between the gender [56]. 
Serum samples were used to investigate sex-specific differences by measuring 
131 metabolites from 3,300 independent individuals. LC/MS/MS was used to 
analyze the samples and linear regression analysis showed significant 
difference between males and females for 102 metabolites out of 131 
metabolites. This shows there is promise in using equine plasma samples for 
metabonomics and gender can also be used as a discriminating factor. 
 
The main aim of doping is to achieve biological changes in certain metabolic 
process that will lead to enhanced performance. Anti-doping analyses could 
detect the different biological changes of the associated metabolic cascade. 






Doping in human sports is usually investigated through endogenous steroid 
profiling. This form of profiling is usually done using GC/MS or isotopic ratio 
mass spectrometry (IRMS) [45]. 
 
The investigation of the metabonomic signature of bike athletes is in-progress 
through a project funded by World anti-doping agency (WADA) in 2006 [45]. 
Another group of researchers used a targeted approach to the detection of 
rhEPO administration [45]. Four urinary metabolites were quantitated by 
LC/MS. The metabolites were asymmetrical dimethylarginine (ADMA), 
symmetrical dimethylarginine (SDMA), arginine and citrulline. It was shown 
that a single dose of rhEPO was sufficient to indicate an increase in all the four 
metabolites. 
 
Both these human studies showed that the introduction of exogenous 
substance can cause changes in the level and ratio of endogenous steroids. 
Therefore metabonomics could be used to study these changes in the 
biological system. 
 
Previous works have been done using metabonomics as a screening tool in 
cattle and horse [57, 58]. For example, metabonomics has been used in 
monitoring the use of AAS in cattle and measuring metabolic changes induced 
by recombinant equine growth hormone (reGH) in horse. For the analysis of 
AAS in cattle urine, the authors used pyrolysis/metastable atom bombardment 





was utilized to discriminate controls from treated animals. LDA also 
correlated to quantitative physiological responses induced by AAS [57]. Work 
has also been done on horse urine samples using liquid chromatography-
electrospray-high resolution mass spectrometry (LC-ESI-HRMS). Their 
preliminary results indicated significant modifications of the metabolome after 
reGH treatment. The chemometirc model was able to differentiate non-treated 
and reGH-treated horses [58]. These studies indicate that metabonomics can 







AIMS AND SIGNIFICANCE OF STUDY 
 
2.1 Targeted approach  
 
In-vivo and in-vitro metabolic studies of turinabol and mesterolone in horses 
were reported previously [32, 33]. Turinabol is a synthetic oral AAS which 
was incubated in horse liver microsomes (HrLM). Five metabolites of 
turinabol were detected with GC/MS (Figure 8). The in-vivo urine samples 
showed no sign of the parent steroid and nine metabolites were detected [33]. 
Mesterolone metabolic study was conducted in a similar way with five 
metabolites detected in-vitro and eight metabolites detected in-vivo (Figure 9) 
[32]. As a result of these studies, there is better understanding of these 
steroids’ pharmacokinetics properties. However, metabolic stability studies of 
other AAS in equine model are lacking.  Metabolic stability studies play a 
vital role in predicting the in-vivo half-life of AAS and hence their clearance 















Figure 9: Mesterolone and its metabolites. Ф- in-vitro metabolites and √- 







Ecdysone and metribolone (Figures 6 and 7) have yet to be studied in equine 
models. Since they have potential for abuse in equine racing, it becomes 
imperative to study their metabolic stabilities via in-vitro equine models. The 
information gleaned from such studies can be used to predict their 
biotransformation in horses and could help identify potential metabolites that 
could be monitored during routine screening. The in-vitro studies could also 
provide information on the clearance time and half-life of ecdysone and 
metribolone. These informations could be used for determining sample 
collection times. 
 
On the other hand, 20-hydroxyecdysone and ethylestrenol (Figures 6 and 7) 
have been studied in the horse model but lack their respective metabolic 
stability studies [25, 26, 59]. As a short acting AAS, metabolic stability studies 
on ethylestrenol can provide useful information on its clearance and half-life. 
Similarly, 20-hydroxyecdysone, a potentially anabolic arthropod derived 
ecdysteroid, lacks information on its metabolic stability. These studies could 
in turn provide the analytical chemist crucial information on the surrogate 
metabolite to measure so as to detect ethylestrenol and 20-hydroxyecdysone 
abuse.   
 
The objective of the targeted approach is to investigate the metabolism of 
ecdysone, 20-hydroxyecdysone, metribolone and ethylestrenol through in-





2.2 Non-targeted approach  
 
Previous studies show that metabonomics can be used to differentiate controls 
from doped animals [57, 58]. As such, non-targeted metabolic profiling 
method, like metabonomics, might also be applied to studying the equine 
metabotypes. With the downstream pharmacologically-induced metabolite 
perturbation likely to be similar for compounds with the AAS backbone 
structures, the non-targeted profiling method might be used as screening 
method for steroid abuse. As biomarkers are hypothesized not to be highly 
variable and dependent on the exact identity of the AAS doping agent, 
changes in the endogenous biomarkers could “suggest” the incident of doping 
without identifying the exact dopant.  
 
Unlike other experimental mammalian models such as rodents, equine plasma 
is considered relatively easier to obtain than urine due to the difficulty for 
horses to urinate at stipulated times. Therefore, plasma is the preferred pre-
race biological matrice to be collected.  
The confounding factors affecting equine plasma samples could be diet, age, 
genetics and gender. The primary diet of race horses housed in the Singapore 
Turf Club is controlled. The average lifespan of a horse is forty years and the 
age of an active race horse typically ranges from two to nine years, which is 
only twenty percent of its life-span. Therefore the age of a race horse is also 





genetic profiles are assumed to be well-conserved. The only possible 
confounding factor is therefore gender. Thoroughbreds are generally divided 
into three genders: males (horse and colt), females (mare and filly) and 
castrated males (geldings). The male horse can be further classified as a rig 
where his testes are not fully formed outside his body but still have the 
characteristics of a horse. With one major confounding factor, non-targeted 
profiling could prove to be an invaluable tool for future monitoring of 
metabolic perturbations related to doping.  
 
The objective of the non-targeted metabolic profiling of horses in the current 
thesis is to identify unique plasma biomarkers of the different genders of 
horses and the unique metabotype related to each gender. Profiling and 
elucidating the basal metabotype of each gender of horses are important as it 
forms the basis for future doping studies of novel AAS that are difficult to 














The summary of this chapter is as follows: 
 
 Specific aims 
Targeted approach To investigate the metabolism of ecdysone, 20-
hydroxyecdysone, metribolone and ethylestrenol. 
This is done through in-vitro metabolic stability 
studies and metabolite identification studies. 
Non-targeted approach To identify unique plasma biomarkers of different 
genders and the unique metabotype related to each 
gender.  
 







MATERIALS AND METHODS 
 
3.1 Targeted approach 
 
3.1.1 Horse liver microsome (HrLM) preparation 
 
3.1.1.1  Chemicals and reagents 
 
All solvents and reagents were of analytical grade. Ultrapure water (18.2 MΩ 
cm) was obtained from a Milli-Q water purification system (Millipore, 
Singapore). 
 
3.1.1.2  Sample preparation 
 
Fresh horse livers were harvested from horses that were euthanized. The livers 
were immediately frozen in liquid nitrogen and stored subsequently at -80°C. 
The livers were homogenized with 12 mL of homogenising buffer (0.1 M 
Tris-Cl, 10 mM EDTA and 150 mM potassium chloride). The homogenate 
was centrifuged at 12,000 g at 4°C for 15 min. The supernatant was decanted 
and further centrifuged at 105,000 g at 4⁰C for 70 min. The supernatant was 





buffer (0.1 M sodium pyrophosphate and 10 mM EDTA). The suspension was 
centrifuged at 105,000 g for 45 min. The supernatant was discarded and 6 mL 
of microsome buffer (0.05 M Tris-Cl, 10 mM EDTA and 20% glycerol) was 
added [60]. 
 
Protein concentration was determined using the Bradford protein assay kit. 
HrLM was diluted to 1 mg/mL protein in 0.2 M phosphate buffer for 
cytochrome P450 and P420 quantification. A few crystals of sodium 
hydrosulfite was added and mixed until dissolved. Carbon monoxide was 
bubbled for 30 sec and the mixture was scanned from 400 to 500 nm. The 
remainder of the liver microsomes was aliquoted and stored at -80°C. 
 
3.1.2 Metabolite identification (Met ID) studies 
 
3.1.2.1 Chemicals and reagents 
 
NADPH was obtained from BD Gentest (MA, U.S.A.). All solvents were of 
analytical grade. Acetonitrile, pyridinium chlorochromate, tetrahydrofuran, 
dichloromethane and lithium aluminium hydride were purchased from Sigma 
Adrich (MO, U.S.A.). Sodium dihydrogen phosphate monohydrate (NaH2PO4) 
and sodium-di hydrogen phosphate (Na2PO4) were obtained from Merck 
(Singapore). Standards for ecdysone, ethylestrenol and norethandrolone were 





were obtained from Sigma (Singapore) and metribolone was from AK 
Scientific (CA, U.S.A.). 17α-ethyl-5α-estrane-3α,17β-diol and 17α-ethyl-5β-
estrane-3α,17β-diol were purchased from the National Measurement Institute 
(NSW, AUS). Prednisolone was purchased from Sigma Aldrich (U.S.A.). 
Trimethylsilyl imidazole (TMSI) and N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA) were obtained from Thermo 
Scientific (U.S.A.). Methoxyamine hydrochloride (MOX) was from Sigma 
Fluka (Singapore). 
 
3.1.2.2 Synthesis of putative 17α-ethyl-5α-estrane-3β,17β-diol and 17α-
ethyl-5β-estrane-3β,17β-diol standards 
 
1.6 mmol of 17α-ethyl-5α-estrane-3α,17β-diol was added to 3 mL to 
dichloromethane containing pyridinium chlorochromate (PCC) (2 mg/mL). 10 
mg of anhydrous sodium acetate was added to the mixture and was incubated 
subsequently at 80⁰C for 2 hr with stirring. The resultant mixture is cooled to 
room temperature and passed through a 3.5 cm Celite column packed in a 
Pasteur pipette. The column was eluted with 5 mL 10% acetone in 
dichloromethane. The resultant solution was dried down and re-constituted 
with 10 mL of tetrahyrofuran (THF). This solution was added dropwise over 1 
hr to a stirring solution of 0.8 mmol of lithium aluminium hydride (LiAlH4) in 
0.8 mL of THF at 0⁰C. This solution was stirred further for another 6 hr under 





hydroxide. After filtering and drying under nitrogen, the residue was re-
constituted in hexane and passed through the Celite column. The column was 
eluted with 5 mL ethyl acetate/hexane (1:2) [61, 62]. The ethyl acetate/hexane 
mixture was dried and derivatized with 50 µL of MOX in pyridine for 30 min 
at 60⁰C followed by 50 µL of TMSI at 60⁰C for 2 h [25]. This experiment was 
repeated with 17α-ethyl-5β-estrane-3α,17β-diol for the synthesis of 17α-ethyl-
5β-estrane-3β,17β-diol.  
 
3.1.2.3 HrLM incubation and sample derivatization 
 
3 µL of 10 mM ethylestrenol was incubated in 11 µL HrLM together with 15 
µL NADPH A, 3 µL NADPH B and 268 µL of 100 mM potassium phosphate 
buffer for 1 h at 37°C. The final reaction mixture contained 1% (v/v) of 
methanol that was used to dissolve the substrate. 150 µL aliquots of the 
incubation mixture were quenched with 300 µL ice-cold acetonitrile at time 
intervals of 0 and 60 min. The experiment was repeated in the absence of 
either NADPH or substrate to yield the negative controls. The quenched 
aliquots were subjected to solid-phase extraction (SPE) and derivatized with 
50 µL of MOX in pyridine for 30 min at 60⁰C followed by 50 µL of TMSI at 
60⁰C for 2 h [25]. The same experiment was repeated for ecdysone, 20-
hydroxyecdysone and metribolone using different derivatisation reagents. 
Ecdysone and 20-hydroxyecdysone were derivatized with 100 µL of 





with 50 µL MOX in pyridine followed by 50 µL of MSTFA/2% TMSI for 30 
min [63]. 
 
3.1.2.4 Chromatographic condition 
 
The GC/TOFMS system (Agilent HP-6890 GC coupled to Waters GCT 
Premier) was used to analyze the derivatized samples. A DB 1MS (30 m x 
0.25 mm x 0.25 μm, Agilent J&W Scientific Folsom, CA, U.S.A.) chemically 
bonded column with 100% dimethylpolysiloxane cross-linked stationary phase 
was used. The carrier gas was helium with the flow rate of 1.0 mL/min and the 
injector was operated in the splitless mode. The injector and source 
temperatures were set at 250⁰C. The oven temperature was kept at 185⁰C at 0 
min and increased at 25⁰C/min to 260⁰C followed by another increase at 
40⁰C/min to 300⁰C where it remained for 16 min. The mass spectrometer was 
operated in electron ionization (EI) mode (70 eV). Data acquisition was 
performed in full scan mode from m/z 100 to 700 with scan time of 1.0 sec.  
Metribolone metabolites were further analyzed using the Thermo Discovery 
LTQ-Obitrap linked to Agilent 1200 LC pump. Chromatography was carried 
out using reverse-phase Sunfire C18 column (5 µm, 2.1 x 150 mm, Waters) 
held at 4⁰C. Mobile phases A and B were 0.15% formic acid in Millipore 
water and acetonitrile, respectively. Gradient chromatography was performed 
at 0.35 mL/min with 80% solvent A and 20% solvent B at the start (t = 0 min), 





min (until t = 14 min). The gradient was then increased to 80% solvent A and 
20% solvent B at t = 14.5 min and held for 1.5 min. Injection volume was 10 
µL each. Ionization was carried out in the positive mode using the electrospray 
source at a capillary temperature of 225⁰C, a sheath gas flow of 30 units, an 
auxiliary gas flow of 5 units and an electrospray voltage of 5 kV. MS/MS 
precursor ion was first isolated in the LTQ and then fragmented at a 
normalized collision energy of 35 V. The full-scan analysis was performed 
over a range from 80 to 350 amu. All data were acquired and processed using 
the Xcalibur version 2.4 software.    
  
3.1.3 Metabolic stability studies 
 
3.1.3.1 Chemicals and reagents 
 
Tris (trimethylol aminomethane) was purchased from Merck (Singapore). 
UGT (uridinediphosphate-glucuronosyltransferase) solutions A and B were 
obtained from BD Gentest (MA, U.S.A.). Saccharolactone and hydrochloric 
acid were purchased from Sigma Aldrich (Singapore) and Fisher Scientific 







3.1.3.2 Sample preparation for Phase I metabolism experiment 
 
10 µL of 50 µM ethylestrenol was incubated in 18 µL HrLM together with 25 
µL NADPH A, 5 µL NADPH B and 442 µL of 100 mM phosphate for 1 h at 
37°C. The final reaction mixture contained 1% (v/v) of methanol that was used 
to dissolve the substrate. 75 µL aliquots of the incubation mixture were 
quenched with 150 µL ice-cold acetonitrile at time intervals of 0, 5, 15, 30, 45 
and 60 min. The experiment was repeated without HrLM, as a control. The 
experiment was repeated for ecdysone, 20-hydroxyecdysone and metribolone. 
Prednisolone was used as internal standard (ISTD). The quenched aliquots 
were dried and re-constituted with 50 µL Millipore water.  
 
3.1.3.3 Sample preparation for Phase II metabolism experiment (for 
ecdysone and 20-hydroxy ecdysone) 
 
100 µL of 250 mM Tris-HCl buffer was mixed with 18 µL HrLM, 182 µL 
Millipore water and 100 µL UGT B and kept on ice for 15 min. 50 µL of 50 
mM saccharolactone and 10 µL of 50 µM of ecdysone or 20-hydroxy 
ecdysone was added and pre-incubated at 37⁰C for 3 min. Finally, 40 µL UGT 
A was added and the mixture was incubated for 1 h at 37°C [64]. The final 
reaction mixture contained 1% (v/v) of methanol that was used to dissolve the 
substrate. 75 µL aliquots of the incubation mixture were quenched with 150 





experiment was repeated without HrLM, as a control. Prednisolone was used 
as ISTD. The quenched aliquots were dried and re-constituted with 50 µL 
Millipore water. 
 
3.1.3.4 Chromatographic condition 
 
Metabolic stability analysis was carried using the Agilent 1290 Infinity LC 
interfaced with Agilent 6430 QQQ MS (Agilent Technologies, CA, U.S.A.). 
The analytical column was reverse-phase Acquity UPLC BEH C18 (1.7 µm, 
2.1 x 50 mm, Waters). The mobile phase was composed of 0.1% formic acid 
in Millipore water as solvent A and 0.1% formic acid in acetonitrile as solvent 
B. Gradient chromatography was performed at 0.6 mL/min with 80% solvent 
A and 20% solvent B at the start (t = 0 min), decreasing to 5% solvent A and 
95% solvent B at t = 1.4 min and hold for 0.5 min (until t = 1.9 min). The 
gradient was then increased to 95% solvent A and 5% solvent B at t = 1.95 
min and held for 0.55 min. This solvent gradient program was used for 
ecdysone, 20-hydroxyecdysone and metribolone. Injection volume was 5 µL 
each. The source was operated in positive electrospray ionisation (ESI) mode. 
The gas temperature was set at 350⁰C. The gas flow and capillary voltage 
were set at 12 mL/min and 3500 V, respectively. Detection of the drugs was 
performed in the multiple reaction monitoring (MRM) mode with single time 





range from 4 to 20 V and fragmentor voltage ranges from 104 to 140 V. 
Results were processed using Agilent MassHunter quantitative analysis. 
 
GraphPad Prism software (version 5, CA, U.S.A.) was used to analyze the 
data and plot the metabolic stability profile. The equation used for one-phase 
exponential decay is Y = Span(e
-KX
)+ plateau where X is time and Y is the 
percentage of substrate remaining with respect to 0 min. The non-linear 
regression results were presented in a semi-log scale to provide a linear 
relationship with respect to incubation time. This helps to visualise data that 
changes with an exponential relationship. This linear relationship would be 
represented by In Y = -KX + In Span where K is the rate elimination constant 
and can be obtained from the gradient of the graph. The half-life of the decay 
was calculated based on In2/K. Since the equation is based on the metabolic 













3.2 Non-targeted approach 
 
3.2.1 Method validation 
 
3.2.1.1 Intra-day and inter-day precision 
 
Intra-day precision was analyzed with seven replicates of pooled plasma 
samples that were processed independently. The inter-day precision was 
determined by analysing the pooled samples on three consecutive days. The 
criteria for acceptability of the precision data were within 20% relative 
standard deviation (RSD). 
  
3.2.1.2 Autosampler stability 
 
Autosampler stability, defined as the stability of the derivatized metabolites 
when stored in the autosampler of the analytical instrument, was also 
evaluated. The stability of the TMS-derivatised metabolites, kept in the 
autosampler at ambient temperature (25  2°C), was determined periodically 
by injecting replicates of the processed samples up to 24 h. The peak areas of 
the selected analytes (leucine, proline, ribose, serine, threonine and valine) 
obtained at the initial run were used as the reference to determine the relative 





based on the availability of their standards and the spread of their retention 
time (RT) over the entire run. The criteria for acceptability of the stability data 
were within 20% RSD. 
 
3.2.1.3 Freezer stability study 
 
Freezer stability of the metabolites in the equine plasma was assessed by 
processing and analysing pooled plasma samples stored at -80°C (for up to 6 
months) and 4°C (for 2 weeks). These temperatures were chosen with relation 
to the workflow of sample analysis at the Singapore Turf Club laboratory. 
Samples stored at -80°C were analyzed on 0, 1, 2, 4, 12 and 24 weeks. 
Samples stored at 4°C were analyzed on 0, 1, 3, 7, 11, 14 days.  
 
3.2.2 Plasma profiling  
 
3.2.2.1 Sample preparation 
 
Prior to sample preparation and GC/TOFMS analysis, all the plasma samples 
were randomized. Equine plasma samples were collected from horse (H, > 3 
year male), rig (R), mare (M, > 3 year female), filly (F, < 3 year female), colt 
(C, < 3 year male) and gelding (G) (n = 25). The collected plasma samples 





ISTD. Acetonitrile (1200 µL) was added to 400 µL of plasma to precipitate the 
proteins. The mixture was vortex-mixed at high speed for 2 min and 
subsequently centrifuged for 20 min at 14000 g. The supernatant was 
separated and evaporated to dryness at 50⁰C under a gentle stream of nitrogen 
gas. The dried extract was derivatized with 60 µL of MSTFA for 45 min at 
60⁰C. Each derivatized extract was transferred to a GC/MS vial.  
 
All the samples were pooled to form the quality control (QC) samples and 
they were also prepared in the same way for GC/TOFMS analysis. 
 
3.2.2.2 Chromatographic condition 
 
The GC/TOFMS system (Agilent HP-6890 GC coupled to Waters GCT 
Premier) was used for the validation of the non-targeted metabolic profiling 
method. A DB 1MS (30 m x 0.25 mm x 0.25 μm, Agilent J&W Scientific 
Folsom, CA, U.S.A.) chemically bonded column with 100% 
dimethylpolysiloxane cross-linked stationary phase was used. The carrier gas 
was helium with the flow rate of 1.0 mL/min and the injector was operated in 
the splitless mode. The injector and source temperatures were set at 250⁰C. 
The oven temperature was kept at 70⁰C for 0.20 min and increased at 
20⁰C/min to 300⁰C where it remained for 5 min. The mass spectrometer was 
operated in EI mode (70 eV). Data acquisition was performed in full scan 





3.2.2.3  Chemometrics analysis 
 
RT correction of peaks was performed using the WATERS MarkerLynx™ 
software with respect to caffeine as ISTD. The total area normalized for each 
sample was performed by dividing the area of each peak by the area of the 
ISTD. The normalization aided in correcting variations due to sample 
preparation and analysis. 
 
All processed data were mean centred and univariate (UV) scaled during 
chemometric data analysis. Normalised samples were exported to SIMCA-P 
(Version 12.0, Umetrics, Umea, Sweden) to perform principal component 
analysis (PCA). PCA is an unsupervised multivariate data analysis technique 
that was used to observe grouping trends and outliers in the data. After PCA 
analysis, the data was subjected to a supervised partial least-squares 
discriminant analysis (PLS-DA) followed by orthogonal partial least-squares 
discriminant analysis (OPLS-DA). This model was used to identify marker 
metabolites to differentiate the different genders of horses. The Q
2 
value is the 
predictive ability of the model and R
2
X value determines the overall 
correlation. 
 
Permutation test with 100 iterations were performed using SIMCA-P software 







RESULTS AND DISCUSSION 
 
4.1  Targeted approach 
 
4.1.1 Results of metabolite identification studies 
 
4.1.1.1  Ethylestrenol 
 
Ethylestrenol was detected at 5.28 min in assays containing HrLM with and 
without cofactors (Figure 10A-D). As expected, the parent drug was absent in 
the controls without substrate (Figure 10E-F).  This confirmed the selectivity 
of our method in detecting ethylestrenol. The HrLM mixtures were compared 
with the standards (Figure 11A-D) and found to match the retention times 
(RT) of norethandrolone (RT = 7.31 min) and ethylestrenol (RT = 5.29 min) 
respectively (Figure 11A and D). The peak (*) at 6.47 min was clearly absent 
in the 0 min incubation sample (Figure 11E) demonstrating that the compound 
was generated during incubation (Figure 11F). A closer look at the time range 
from 5.80 to 7.50 min, revealed that the RT for neither 17α-ethyl-5β-estrane-
3α,17β-diol (Figure 12A) nor 17α-ethyl-5α-estrane-3α,17β-diol (Figure 12B) 
standards matched the peak (*) at 6.47 min in the 60 min HrLM assay (Figure 





ethyl-5β-estrane-3α,17β-diol standards (Figure 13A and B) were compared 
with the unknown peak at 6.47 min (Figure 13C), the former standard mass 
spectrum (Figure 13A) matched better with the unknown peak mass spectrum 
(Figure 13C). The spectra of 17α-ethyl-5α-estrane-3α,17β-diol and 17α-ethyl-
5β-estrane-3α,17β-diol differed by the presence of the ion at m/z 331 in the 
latter and absence in the former standard (Figure 13A and B). The absence of 
this ion in both the spectra of 17α-ethyl-5α-estrane-3α,17β-diol and the 
unknown metabolite detected in HrLM (Figure 13A and C) further confirmed 
the similarity of their spectra. This indicated that the unknown metabolite (*) 
at 6.47 min was potentially generated via metabolism of ethylestrenol by the 
HrLM as it shares the same chemical backbones as the other known 
metabolites of ethylestrenol.  
 
The chromatograms indicated the RT of the putative chemically-synthesized 
17α-ethyl-5β-estrane-3β,17β-diol and 17α-ethyl-5α-estrane-3β,17β-diol 
standards  were 6.12 and 6.35 min, respectively (Figure 14A and B). The RT 
of the 5α-isomer was closer to the unknown peak of interest in the HrLM 
(Figure 14C). The mass spectrum of the chemically-synthesised 17α-ethyl-5α-
estrane-3β,17β-diol (Figure 15A) was a better match to the unknown 






 Figure 10: Chromatograms of ethylestrenol incubated with (A) HrLM at 0 
min, (B) HrLM at 60 min, (C) HrLM mixture without cofactor at 0 min, (D) 
HrLM mixture without cofactor at 60 min, (E) HrLM mixture without 
substrate at 0 min and (F) HrLM mixture without substrate at 60 min. The 







Figure 11: Chromatograms of standards and HrLM mixture. (A) 
norethandrolone standard (B) 17α-ethyl-5α-estrane-3α,17β-diol standard (C) 
17α-ethyl-5β-estrane-3α,17β-diol standard (D) ethylestrenol standard (E) 
HrLM mixture at 0 min and (F) HrLM mixture at 60 min. The analytes were 







Figure 12: Chromatograms of standards and HrLM mixture. (A) 17α-ethyl-5β-
estrane-3α,17β-diol standard, (B) 17α-ethyl-5α-estrane-3α,17β-diol standard 
and (C) HrLM mixture at 60 min. The analytes were derivatized with their 







Figure 13: Mass spectra of (A) 17α-ethyl-5α-estrane-3α,17β-diol standard (B) 
17α-ethyl-5β-estrane-3α,17β-diol standard and (C) unknown metabolite (peak 








Figure 14: Chromatograms of HrLM mixture with synthezised standards. (A) 
17α-ethyl-5β-estrane-3β,17β-diol (putative) standard (B) 17α-ethyl-5α-
estrane-3β,17β-diol (putative) standard and (C) unknown metabolite (peak at 
6.47 min) in HrLM mixture at 60 min. The analytes were derivatized with 







Figure 15: Mass spectra of (A) 17α-ethyl-5α-estrane-3β,17β-diol (putative) 
standard and (B) unknown metabolite (peak at 6.47 min) in HrLM mixture at 
60 min. 
 
4.1.1.2  Ecdysone 
 
The metabolism of ecdysone had been well characterized in Pieris larvae 
(Figure 16) [65]. 20-hydroxy ecdysone and ecdysone standards were detected 
at RT 21.96 and 19.25 min, respectively (Figure 17A and B). The parent drug, 
ecdysone, was detected in the HrLM assays in the presence and absence of 
cofactors (Figure 17C-F). On the other hand, the parent drug was absent in the 
negative controls (Figure 17G-H). The RT of the parent drug matched that of 





metabolite of ecdysone, 20-hydroxy ecdysone (RT = 21.96 min, Figure 17A) 
was absent (Figure 17D). Furthermore, the intensity of the parent drug was 










Figure 17: Chromatograms of (A) 20-hydroxy ecdysone standard, (B) 
ecdysone standard, (C) HrLM mixture at 0 min, (D) HrLM mixture at 60 min, 
(E) HrLM mixture without cofactor at 0 min, (F) HrLM mixture without 
cofactor at 60 min, (G) HrLM mixture without substrate at 0 min and (H) 
HrLM mixture without substrate at 60 min. The analytes were derivatized with 
their respective derivatizing agents. 
 
The fragmentation pattern of derivatized ecdysone standard (Figure 18A) 
comprised product ions at m/z 131 and 171 that corresponded to mass losses 
from the C17 side chain. The molecular ion of the fully silylated ecdysone (M
+
, 





of a fully silylated ecdysone [66]. Figure 18B shows the mass spectrum of 
ecdysone as detected in the HrLM mixture at 60 min. 
 
 
Figure 18: Mass spectra of (A) derivatized ecdysone standard and (B) 
derivatized ecdysone (peak at 19.20 min) in HrLM mixture at 60 min. 
 
4.1.1.3 20-hydroxy ecdysone  
 
The metabolites of 20-hydroxy ecdysone in humans were reported to be 2-







Figure 19: 20-hydroxy ecdysone and its metabolites in humans. 
 
20-hydroxy ecdysone standard was detected at RT 21.96 min (Figure 20A). 
The parent drug was detected in the HrLM mixtures with and without cofactor 
(Figure 20B-E). As expected, 20-hydroxy ecdysone was absent in the negative 
controls (Figure 20F-G). The RT of the parent drug, 20-hydroxy ecdysone, 
matched with the standard (RT = 21.96 min, Figure 20A). The intensity of the 
parent drug was consistent throughout the 60 min incubation period (Figure 






Figure 20: Chromatograms of (A) 20-hydroxy ecdysone standard, (B) HrLM 
mixture at 0 min, (C) HrLM mixture at 60 min, (D) HrLM mixture without 
cofactor at 0 min, (E) HrLM mixture without cofactor at 60 min, (F) HrLM 
mixture without substrate at 0 min and (G) HrLM mixture without substrate at 
60 min. The analytes were derivatized with their respective derivatizing 
agents. 
 
20-Hydroxy ecdysone also needs long reaction times similar to ecdysone for 
GC/MS analysis. The fragmentation pattern (Figure 21) is also similar to 
ecdysone with product ions detected at m/z 131, 147 and 171. The ion m/z 561 
arises from cleavage of the side chain between C20 and C22 followed by the 





ion at 561 has been previously reported to be a suitable screening ion [24]. 





Figure 21: Mass spectra of (A) 20-hydroxy ecdysone standard and (B) parent 












There is no reported metabolite of metribolone [67]. The RT of metribolone 
standard was 6.98 min (Figure 22A). The parent drug, metribolone, was 
detected in the HrLM mixture in the presence and absence of cofactors (Figure 
22B-E). The RT of the parent drug in the HrLM mixtures matched the RT of 
metribolone standard (RT = 6.98 min, Figure 22A). The parent drug was not 
detected in the negative controls (Figure 22F-G). In the 60 min HrLM 
incubation mixture, the peak intensity of the parent drug decreased 
significantly over time indicating that the metabolism of metribolone had 
taken place (Figure 22B-C). 
 
A closer look of the chromatogram showed that metribolone had been 
metabolized within the 60 min incubation period (Figure 23B-C). In the 0 min 
HrLM incubation mixture, metribolone peak area was 880 units whereas after 
60 min, the peak area decreased significantly to 97 units. The mass spectrum 
of the 60 min HrLM mixture also suggested the presence of the parent drug 







Figure 22: Chromatograms of (A) metribolone standard, (B) HrLM mixture at 
0 min, (C) HrLM mixture at 60 min, (D) HrLM mixture without cofactor at 0 
min, (E) HrLM mixture without cofactor at 60 min, (F) HrLM mixture without 
substrate at 0 min and (G) HrLM mixture without substrate at 60 min. The 






Figure 23: Expanded view of the chromatograms (A) metribolone standard, 
(B) HrLM mixture at 0 min, (C) HrLM mixture at 60 min, (D) HrLM mixture 
without cofactor at 0 min, (E) HrLM mixture without cofactor at 60 min, (F) 
HrLM mixture without substrate at 0 min and (G) HrLM mixture without 







Figure 24: Mass spectra of (A) metribolone and (B) parent drug (peak at 6.98 
min) in HrLM mixture at 60 min. 
 
The 60 min HrLM mixture was further analyzed for possible metabolites using 
the Thermo Obitrap. It was observed from the data that there were multiple 
possible metabolites. Due to the poor intensities of most of the peaks, only the 






Figure 25: (A) Chromatogram of possible metribolone metabolites (B) mass 
spectrum of unknown compound at RT 4.24 min and (C) expanded mass 
spectrum (m/z 160 to 230) of unknown compound at RT 4.24 min. The 





The unknown compound at RT 4.24 min has the highest intensity compared to 
the rest of the analytes at 4.85 min and 5.13 min, respectively (Figure 25A). 
The m/z of 227 ion was extracted from the chromatogram as it was diagnostic 
of the 4,9,11- triene structure (Figure 25B). Similarly, the ions at m/z 165.2 
and 211.1 are diagnostic of the 4,9,11-triene family (Figure 25C) [68].  
 






Metribolone C19H24O2 285.18491 285.18546 1.9 
16-hydroxy 
metribolone 
C19H24O3 301.17982 301.18030 1.6 
 Table 2: Accurate mass measurement of metribolone and metabolite B, 
16-hydroxy metribolone 
 
The elemental compositions of the postulated metabolite B was further 
confirmed using accurate mass measurement. The comparison of the 











4.1.2 Results of metabolic stability studies 
 
4.1.2.1 Testosterone (positive control) 
 
Testosterone was chosen as positive control for both Phase I and II metabolic 
stability experiments to validate the enzymatic activity of HrLM and the 
suitability of the assay. In experiments conducted with Phase I cofactors, 
NADPH, the metabolic half-life was calculated to be 0.43 min. The 
elimination rate constant, K, was calculated to be 1.60 min
-1
. The percentage 
of testosterone in the control remained consistent throughout the 5 min 
incubation period while it decreased gradually in the HrLM mixture (Figure 
26). 
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In Phase II metabolic stability experiments with UGT as cofactors, the half-
life of testosterone was calculated to be 9.10 min. The elimination rate 
constant was calculated to be 0.077 min
-1
, suggesting that conjugation 
metabolism had taken place (Figure 27). 
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Figure 27: Phase II metabolic profile of testosterone (positive control). 
 
4.1.2.2  Ethylestrenol 
 
Ethylestrenol was not functionally amenable for ionisation via LC/MS/MS as 
it did not have any ionisable sites. Therefore metabolic stability assay was not 











Ecdysone metabolic stability samples were analyzed in triplicates. The results 
showed that ecdysone was metabolically stable over the 60 min incubation 
period (Figure 28). Increasing trends were observed for both the controls and 
HrLM samples. The reasons of the increasing trends were unknown but they 
were reproducible when the experiments were repeated. The percentage 
substrate remaining was above 100% over the 60 min incubation period. This 
was consistent with the metabolite identification studies where metabolite of 
the parent drug was also not observed. Further experiments with UGT were 
carried out to evaluate the potential Phase II metabolism of ecdysone. 
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 Figure 28: Phase I metabolic stability profile of ecdysone. 
 
Ecdysone was also found to be metabolically stable in the Phase II UGT 
metabolism assays (Figure 29). The profile was found to be similar to the 





substrate remaining were also observed in both control and HrLM assays. 
While the trend was reproducible, the reason accounting for it remained 
unknown. 
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 Figure 29: Phase II metabolic stability profile of ecdysone. 
 
4.1.2.4 20-Hydroxy ecdysone 
 
Metabolic stability assay samples of 20-hydroxy ecdysone demonstrated first 
order metabolic degradation profile (Figure 30). Although the substrate in the 
control was increasing over the 60 min incubation period, the substrate in the 
HrLM mixture was decreasing over time. This suggested that 20-hydroxy 
ecdysone underwent metabolism. The elimination rate constant, K, and half-




 and 3.2 x 10
6
 min, respectively. This 
was inconsistent with the metabolite identification results where metabolite of 





evaluate Phase II metabolism of 20-hydroxy ecdysone via UGT conjugation 
were carried out. 
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Figure 30: Phase I metabolic stability profile of 20-hydroxy ecdysone. 
 
Phase II experiments demonstrated that 20-hydroxy ecdysone was 
metabolically stable (Figure 31). The percentage of substrate remaining in the 
control and HrLM incubation mixtures remained consistent over the 60 min 
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Figure 31: Phase II metabolic stability profile of 20-hydroxy ecdysone. 
 
4.1.2.5  Metribolone 
 
The result of metabolic stability assay of metribolone was consistent with that 
of its metabolite identification assay. The metabolic stability assay of 
metribolone demonstrated its first order metabolic degradation profile (Figure 
32) [69]. The percentage of substrate remaining in the control was consistent 
throughout the 60 min incubation. The percentage substrate remaining in the 
HrLM assay decreased gradually over the 60 min incubation period. The value 
for K was calculated to be 0.032 min
-1
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The metabolites of ethylestrenol postulated in the current study seemed similar 







Figure 33: Ethylestrenol and its metabolites [26]. 
 
The differences in the ion intensities of ethylestrenol at 0 and 60 min (RT = 
5.2 min, Figure 11E and F) and the development of new peaks at 6.47 and 7.33 
min after incubation indicated that metabolism of ethylestrenol had taken 
place. The analyte at RT 7.33 min matched the RT of norethandrolone 
standard at 7.31 min (Figure 11A and F). The analyte at 6.47 min in the 60 
min HrLM incubation mixture could not be identified chromatographically 
using the standards (17α-ethyl-5α-estrane-3α,17β-diol and 17α-ethyl-5β-
estrane-3α,17β-diol) available in the laboratory (Figure 12). This prompted the 
further investigation of this unknown metabolite. The mass spectrum of the 
unknown metabolite was compared subsequently with the mass spectra of the 







In Figure 13, the data suggested that the cleavages between C14 and C15, and 
C13 and C17 produced ion at m/z 157 which is specific to the D-ring 
fragmentation. The fragmentation of the D-ring with TMS ether at C17 is 
extensive due to a destabilizing bond between the C13 and C17 [70].  The ions 
at m/z 157, 144 and 241 corresponded to the loss of TMS and ethyl group from 
the molecular ion (m/z = 450). While the RT of the unknown metabolite did 
not match putative standards (Figure 14), the spectrum was a closer match to 
the putative 17α-ethyl-5α-estrane-3β,17β-diol standard. It was postulated that 
the unknown metabolite could be associated with the 5α-isomer with 
variations of the hydroxyl group in the C3 position. 
 
A further attempt was made to identify 19-norpregnane-3,17-diol. Hence, 17α-
ethyl-5α-estrane-3α,17β-diol and 17α-ethyl-5β-estrane-3α,17β-diol were 
oxidized with pyridinium chlorochromate (PCC) and reduced with 
tetrahyrofuran (THF) to synthesize a mixture of the corresponding 3α and 3β 







Figure 34: Schematic flow of synthesis. 
 
Since the 3α-isomers standards did not match the RT of the unknown 
metabolite (RT = 6.47 min), we proceeded to compare the putative 3β-isomer 
standards (Figure 14). The unknown metabolite shared a closer RT with the 
5α,3β- isomer standard (RT = 6.35 min) than 5β,3β- isomer standard (RT = 
6.12 min). While the mass spectra of the unknown metabolite and the putative 
5α,3β- isomer correlated well with each other, we still could not confirm the 






The mass spectrum of the unknown metabolite is comparable to those in-vitro 
studies on cattle and rat (Figure 35) [27, 28]. This shows that horses may 
metabolize ethylestrenol in a similar way as cattle and rat. As the synthesized 
standard was not adopted in the previous studies, our current results provided a 
better understanding of the possible structure of the metabolite. 
 
4.1.3.1.2 Ecdysone and 20-hydroxy ecdysone 
 
The analysis of ecdysteroids in GC-MS was problematic due to their complex 
structures. Long derivatisation times were required (24 h) as the C14 and C20 
hydroxyl groups were found to be silylated with difficulty. When MSTFA/2% 
TMSI was used, the keto-TMS derivatives were produced. As there is a lack of 
information of ecdysone in mammals, it is assumed that the metabolism 







Figure 35: Mass spectra of ethylestrenol metabolite in (A) cattle and (B) rat 
[27, 28]. 
 
20-hydroxy ecdysone is the major metabolite of ecdysone. This metabolite 
was not observed in the current experiment due to the lack of Phase I 
metabolism. This was also evident from the lack of change in the peak 





20-hydroxy ecdysone has been reported to be further metabolized differently 
in different species [71]. In humans, 20-hydroxy ecdysone metabolizes into 
deoxylated metabolites (Figure 19) and does not yield 20,26-dihydroxylated 
product as indicated in Figure 16 [24]. The 20,26-dihydroxylated product has 
only been reported in decapods  crustaceans [72]. Therefore 20,26-dihydroxy 
ecdysone was not expected in this experiment. 
 
The trend observed in the Phase I metabolism of 20-hydroxy ecdysone in our 
study was inconsistent with met ID study. In the met ID study of 20-hydroxy 
ecdysone, no metabolites were observed. The lack of Phase I metabolism of 
20-hydroxy ecdysone was supported in a recently published literature [59]. In 
this paper, Phase I experiments of 20-hydroxy ecdysone was conducted in 
equine liver microsomes and S9 fraction. None of the 20-hydroxy ecdysone 
metabolites were detected in LC- or GC-MS. Although the study was done in 
triplicate, the trend observed was consistent. Therefore the observed trend 
could not be explained.  
 
The lack of Phase I metabolism of ecdysone and 20-hydroxy ecdysone 
indicated that HrLM did not hydroxylate neither ecdysone nor 20-hydroxy 
ecdysone. One possible explanation for the lack of Phase I metabolism could 
be that ecdysone and 20-hydroxy ecdysone undergo Phase II metabolism that 
was not tested in the current HrLM assay. However, due to the hydrophilic 
nature of ecdysone and 20-hydroxy ecdysone, it is also reasonable to assume 





via the kidney. In addition, in an earlier study performed in calves [73], 20-
hydroxy ecdysone was also measured in its native form for the monitoring of 
its fraudulent doping in the animals. Together with our findings, we confirmed 
that it would be more relevant to monitor the parent drug of ecdysone and 20-




With metribolone indicating Phase I metabolism, possible metabolites were 
predicted based on similar 4,9,11-triene AAS and  THG structures (Figure 36) 
[67, 68]. To identify the possible metabolites, further structural elucidations of 
the metabolite were performed using the Orbitrap mass analyzer. 
 
The ion at m/z 301.2 was the parent ion while the product ion at m/z 265.2 was 
derived from the loss of two water molecules from the parent ion (Figure 25). 
Since the 4,9,11-triene structure was found to be intact without any 
modifications, it was postulated that the loss of water would probably be due 
to the loss of hydroxyl group at positions C16 and C17. This suggested that the 
possible metabolite in the microsome assay could be metabolite B (Figure 36). 
The comparison of the experimental masses with the calculated values did not 
deviate significantly (< 2 ppm), confirming the identity of metabolite B to be 







Figure 36: Structures of metribolone and its possible metabolites. (A) 18-
hydroxy metribolone (B) 16-hydroxy metribolone (C) 6-hydroxy metribolone 
and (D) 2,16-dihydroxy metribolone. 
4.1.3.2 Metabolic stability studies 
  
The testosterone control assay was not performed on neither human nor mouse 
liver microsomes. However, testosterone had been used in inhibition studies 





testosterone formation using human hepatocytes and liver microsomes. These 
experiments were the study of 6β-hydroxy testosterone formation whereas this 
study was on the decay of testosterone. Moreover, the parameters indicated in 
the literature were Km and Vmax. These parameters were not comparable to the 
half-life calculation used in this study. Therefore we were unable to 
extrapolate this data to the current study. 
 
The increasing trend observed in Figure 28 for ecdysone was consistently 
observed in three independent assays and was unexpected. Nevertheless, it 
was obvious that Phase I metabolism had not taken place. This result was 
consistent with the respective metabolic identification results where metabolite 
of ecdysone was absent. 
 
Similar results were observed for 20-hydroxy ecdysone. The diverging trends 
(Figure 30) observed in the metabolic stability study of 20-hydroxy ecdysone 
were unexpected. These trends were initially postulated to be attributed to the 
instability of the parent substrate in the autosampler. In the initial experiment, 
the 60 min assay samples were injected first to prevent carry-over followed by 
samples of other time-points. It was speculated that the analytes belonging to 
the later injections could have degraded while stored in the autosampler 
leading to the observed trend. This was further investigated with a reverse-
order analysis but the outcome remained unchanged. In our study, testosterone 
was used as positive control and subjected to the same HrLM study. The result 





profile (Figure 26). Therefore, the non-degrading Phase I trends observed for 
ecdysone and 20-hydroxy ecdysone could be unique for these compounds in 
HrLM. Further experiments including UGT cofactors were performed to 
investigate if ecdysone is susceptible to Phase II metabolism. 
 
The trends observed in both the control and HrLM assay, indicated the lack of 
Phase II metabolism of ecdysone (Figure 29). Three independent sets of assays 
were analyzed and similar trends were observed. The Phase II metabolic 
stability profile of 20-hydroxy ecdysone showed diverging trend (Figure 31). 
The experiment was repeated but the same trend was observed. As positive 
controls demonstrated that the HrLM was metabolically active (Figure 27), 
these trends observed could be unique to this family of steroids.  One possible 
reason for the lack of Phase II activities in ecdysteroids could be due to the 
innate nature of HrLM. Ecdysteroids studies in insects have been reported to 
have phosphate esters as the major metabolite in Phase II metabolic reactions 
[76]. Such phosphorylation conjugation reaction of 20-hydroxy ecdysone 
should be tested in future study. 
 
With first-order degradation profile (Figure 32), metribolone demonstrated 
Phase I metabolism. The half-life of metribolone was slower compared to 
testosterone in HrLM under similar conditions (K = 1.60 min
-1
 and half-life = 
0.43 min). This indicated that metribolone took a longer time to decrease by 
half its original value. The elimination rate constant also suggested that 





slower rate. In order to understand the implication of the metabolism of 
metribolone in the detection of horse doping, further in-vitro to in-vivo scaling 
or in-vivo pharmacokinetics studies in horses need to be performed. In the near 
future, the monitoring of both metribolone and its metabolite may be essential 




The summary of the targeted approach results is as follows: 
 
 Ethylestrenol Ecdysone 20-hydroxy 
ecdysone 
Metribolone 




















trend could not 
be explained 






with half-life = 
0.43 min and  












4.2 Non-targeted approach 
 
4.2.1 Method validation 
 
4.2.1.1 Results of intra-day and inter-day precision 
 
Seven injections were done on the same day for intra-day precision. Inter-day 
precision was determined by analyzing injections (seven each day) carried out 
over three consecutive days. The different values of the internal standard and 
six selected endogenous metabolites in the TMS derivatized plasma samples 
are shown in Figure 37 and 38.  
 
The RSDs for the intra-day precision were below 20% (Figure 37). The RSDs 
for caffeine (ISTD), L-valine, L-isoleucine, proline, L-serine, threonine and 
ribose were 4.9, 8.1, 12.2, 13.0, 6.5, 6.0 and 14.2%, respectively. 
 
The inter-day precision for the selected metabolites and ISTD were also below 
20% (Figure 38). The RSDs for caffeine (ISTD), L-valine, L-isoleucine, 








Figure 37: Relative standard deviation of intra-day precision of ISTD and six 
endogenous metabolites in equine plasma. 
 
 
Figure 38: Relative standard deviation of inter-day precision of ISTD and six 


































4.2.1.2  Results of autosampler stability 
 
Autosampler stability of the derivatized plasma samples was evaluated for 24 
h. RSDs of ribose and L-serine were slightly higher than 20% at 24.6 and 
22.3%, respectively (Figure 39). 
 
 
Figure 39: Relative standard deviation of autosampler stability of ISTD and 
six endogenous metabolites in equine plasma. 
 
4.2.1.3 Results of freezer stability 
 
The metabolites were relatively stable over the two weeks except for L-
isoleucine, ribose and L-serine when plasma samples were stored at 4⁰C 

















Figure 40: Stability of ISTD and six endogenous metabolites over two weeks 
stored at 4⁰C with respect to day 0. 
 
Plasma samples stored at -80⁰C were analyzed over a six month period. L-
isoleucine and ribose RSDs varied between week 1 and week 24 indicating 
their instability, similar to storage at 4⁰C (Figure 41). Valine metabolite 


























Figure 41: Stability of ISTD and six endogenous metabolites over six months 




The randomized equine plasma samples were analyzed using the SIMCA-P 
software. The PCA was plotted with the different genders of horses and six 
QCs (Figure 42). One of the colt plasma samples was a severe outlier. The six 
QC samples were clustered loosely around the centre of the eclipse. The Q
2 
value for this plot was 0.115 and the R
2






















Figure 42: PCA plot obtained from equine plasma samples of different 
genders of horses with QC samples. H = horse, G = gelding, M = mare, R = 
rig, F = filly, C = colt and QC = quality control samples. 
 
For a better comparison of the clustering, the QC samples and outlier were 
removed from the plot (Figure 43). There was obvious clustering between the 
males (H and C) and the females (F and M).  The Q
2
 value was 0.0919 and the 
R
2
X value was 0.376. 
 
The OPLS-DA plot obtained from the male horse (horse, colt and rig) and 
female horses (mare and filly) indicated that each gender was indeed clustered 
(Figure 44). The Q
2
 value was 0.368, R
2
X value was 0.347 and R
2







Figure 43: PCA plot obtained from all equine plasma samples, without QC 
samples and outlier. H = horse, G = gelding, M = mare, R = rig, F = filly and 
C = colt. 
 
 
Figure 44: OPLS-DA plot obtained from male horses and female horses. H = 





Male horses (horse, colt and rig) were compared with gelding horses in the 
OPLS-DA plot (Figure 45). The male horses were clearly discriminated from 
the gelding horses. It was obvious that the male horses had some similar 
characteristics within the group as they clustered together regardless of their 
age and different development stages. The Q
2
 value was 0.0696, R
2
X value 
was 0.293 and R
2
Y was 0.906. 
 
 
Figure 45: OPLS-DA plot obtained from male horses and gelding horses. H = 
horse, G = gelding, R = rig and C = colt. 
 
Female horses (mare and filly) were compared with gelding horses in the 
OPLS-DA plot (Figure 46). The female horses were well discriminated from 
the gelding horses. The Q
2
 value was 0.175, R
2









Figure 46: OPLS-DA plot obtained from female horses and gelding horses. G 
= gelding, M = mare and F = filly. 
 





the original data and the permutated data. The OPLS-DA models were 




 values of the validated OPLS-DA model 
for the male and female horses were 0.931 and 0.191, respectively (Figure 





 values of 0.944 and 0.200, respectively (Figure 47B). The validation of 




 values of 0.948 and 0.311, 
respectively (Figure 47C).  For the three validation plots (Figure 47A-C), the 
lines joining the original and permutated Q
2
 values cut the y-axis within the 
positive regions. In addition, some permutated Q
2
 values were clearly greater 
than the original Q
2







Figure 47: Validation plot of OPLS plots. A = OPLS for male horses and 
female horses, B = OPLS for male horses and gelding horses and C = OPLS 









The storage of the plasma samples in the Singapore Turf Club is regulated by 
the release of the final analytical report to the stipendiary stewards. Samples 
are usually stored at 4⁰C for two weeks while the analysis is in-progress. After 
two weeks, the final analytical results are released and negative samples are 
discarded. Longer term storage is done at -80⁰C. 
 
The six endogenous metabolites were chosen based on the availability of their 
standards and the spread of their retention times over the entire analytical 
runtime. These endogenous metabolites were chosen for the purpose of 
validating the analytical method and may not be used as biomarkers in actual 
samples. 
 
The precision data for the intra-day and inter-day pooled plasma samples 
demonstrated RSD within 20% and were found to be satisfactory. Ribose and 
L-serine were suspected to be unstable as their RSDs were slightly higher than 
20% (Figure 37 and 38). Therefore the plasma samples were analyzed within 
24 h of derivatisation. 
 
Ribose, L-isoleucine and L-serine were suspected to be unstable at 4⁰C as 
their RSDs were higher than 20% (Figure 40). The variations of ribose seemed 





multiple peaks of ribose have degraded. RSD of L-isoleucine remained above 
20% throughout the 14-day period. L-serine RSD varied on the seventh and 
eleventh day indicating its instability. Therefore the metabolites found to 
unstable when stored at 4⁰C for 14-day period (ribose, L-isoleucine and L-
serine) should be interpreted prudently in the subsequent metabonomics study. 
 
Plasma samples stored at -80⁰C showed variations in some of the endogenous 
metabolites (Figure 41). L-isoleucine had a high variation (RSD = 34.99%) in 
the first week but it decreased significantly in the second week to less than 
1%. However, it gradually increased over the next twenty weeks. Similarly, 
ribose had the same trend. This indicated the instability of L-isoleucine and 
ribose over 24 weeks. Valine degraded after 12 weeks. L-serine metabolite 
was more stable when the plasma samples were stored at -80⁰C (Figure 41) 
with their RSD was below 20%. The plasma samples were more stable when 
stored at -80⁰C than at 4⁰C. Therefore plasma samples should preferably be 
stored at -80⁰C for metabonomics studies. Ribose and L-isoleucine should be 
interpreted prudently in the subsequent metabonomics study due to their 
instability. The samples should be processed and analyzed within 12 weeks of 
storage. 
 
PCA is an unsupervised mathematical procedure that uses an orthogonal 
transformation to convert a set of observations of possibly correlated variables 





Partial least-squares (PLS) method is used when a qualitative relationship 
between two data tables X and Y is desired. X mainly consists of spectral or 
chromatographic data and Y contains quantitative values like concentration of 
endogenous metabolites. When PLS is used for discriminant analysis, it is 
known as PLS-DA, where the Y matrix contains qualitative values like gender. 
OPLS is a modification of supervised PLS analysis. In OPLS, the systematic 
variations of X are separated into two parts. The two parts consist of one part 
linearly related to Y and the other orthogonally related to Y [77, 78]. These 
different chemometric analyses are necesary to generate interpretable models 
for the collected data. 
 
This analysis had 31 observations and 2214 variables. PCA plots are used to 
observe the trends and outliers in the variables being analyzed. PCA is a form 
of unsupervised technique that was used to check the validity of the data in 
metabonomics analysis. Figure 42 showed the QC samples were loosely 
clustered indicating probable inconsistency in the preparation of the samples 
and the analytical method. The PCA indicated some clustering between the 
genders, hence the QCs were removed to investigate if it was true (Figure 43). 
The female horses (mare and filly) were clustered away from the male horses 
(horse, colt and rig). There seem to be separated by the second componenet 
(t[2]). Unsupervised PCA was followed by a supervised technique, OPLS-DA.  
 
Figure 44 shows the discrimination between the male and the female horses. 





The separation within the cluster indicates within-class variation. To 
demonstrate the differences between the male horses and the gelding horses, 
the samples were subjected to OPLS-DA analysis (Figure 45). The male and 
the gelding horses were differentiated by the first latent variable, t[1]. 
Similarly, the female horses were differentiated from the gelding horses by the 
first latent variable (Figure 46).  
 
Although, the PCA plot indicated clustering of the different genders, the Q
2
 
values were less than 0.5. The validation plots (Figure 47) indicated the failure 
of the model as the Q
2
 regression line did not have a negative intercept and all 
the permuted Q
2
 values on the left were of the same level as the original point 
to the right. Therefore OPLS-DA models (Figure 44 - 46) were not robust and 
validated. 
 
The overlays of the QC samples and their ISTD indicated the consistency of 
the analytical method (Figure 48 and 49). Hence, the low Q
2
 values and poor 











Figure 49: An overlay of GC/MS extracted chromatograms of caffeine (ISTD 
at RT = 8.67 min) in the six QC samples. 
 
the raw data since re-processing of the data and chemometrics analysis did not 
yield any improvement. Therefore the current analytical method may not be 










5.1.1 Targeted approach 
 
Ethylestrenol metabolite identification experiment confirmed that local horses 
in Singapore metabolize ethylestrenol in a similar way to other race horses, 
cattles and rats [25, 27, 28]. From the small-scale synthesis experiment, it is 
also clearer that the unknown metabolite could possibly be associated with 
17α-ethyl-5α-estrane-3β,17β diol. The met ID experiment could be extended 
longer than 60 min to observe more metabolites. 
 
Liver microsomes was found to be a suitable enzymatic system to study Phase 
I and II metabolism of ecdysone and 20-hydroxyecdysone in horses due to the 
stability of the enzymes and availability of horse livers. The use of different 
cofactors also facilitated our investigation of the Phase I and II metabolism of 
the substrate. Our study confirmed that it would be more appropriate to 
monitor the parent drug of ecdysone and 20-hydroxy ecdysone in dope testing, 






In-vitro metabolism study on metribolone in our study yielded novel results. 
Metribolone showed Phase I metabolism and first order metabolic degradation 
profile. Further experiments suggested that 16-hydroxy metribolone could be 
the major metabolite of metribolone. Further in-vitro and in-vivo 
pharmacokinetics studies need to be performed to determine whether it is more 
accurate to screen for doped metribolone or its metabolite in horse racing. 
 
In conclusion, our study demonstrated that metabolic stability studies and met 
ID studies provide valuable information in the fight against doping through 
elucidating the biotransformation of the doped drugs to their metabolites from 
a kinetic perspective. While it is not a common practice to perform in-vitro 
metabolism studies in horse racing laboratory currently such studies should be 
incorporated as a core research and development effort in the future to 
determine the optimal analyte (parent drug or metabolite) for routine 
screening. 
 
5.1.2 Non-targeted approach 
 
To our best knowledge, there had been no reports on non-targeted profiling of 
equine plasma. However metabolic profiling of human biological fluids 
showed no indication of instability for these metabolites [79]. Therefore 





The global plasma profiling of equine plasma was unsuccessful as the 
developed prediction models are not robust and validated. However the broad 
observed trends indicate the potential of the chemometric models in 
differentiating the different genders of horses. Therefore with better analytical 
methods and larger sample size, this model could still be used to identify 
unique plasma biomarkers of the horse genders. Identifying the unique 
baseline metabotype of each gender is an important preliminary step before 
metabonomic can be further explored to detect perturbations of the 
metabotype related to doping. 
 
5.2 Future work 
 
5.2.1 Targeted approach 
 
The predicted metabolite 17α-ethyl-5α-estrane-3β,17β diol could be 
synthesised in a larger scale. The unknown metabolites could be synthesized 
in larger quantities, purified and crystallized. Elemental analysis could be 
performed to confirm the elemental composition. NMR could also be used to 
elucidate the structure of the metabolites. The product could also be further 
structurally characterized and analyzed with in-vivo samples derived from 
ethylestrenol administration. The identity of the putative metabolite could give 





samples. As such, this could aid the chemist to deduce confidently 
ethylestrenol abuse. 
 
The metabolic stability assay of testosterone could be studied using human and 
mouse liver microsomes in order to better understand the metabolic capacity 
of HrLM. 
  
Ecdysone and 20-hydroxy ecdysone could be studied in horse hepatocytes to 
have a better understanding of their Phase II activities. This could be used to 
investigate the possibility of phosphorylation of ecdysone and 20-hydroxy 
ecdysone in equine as reported in insects. These Phase II activities could be 
further verified with in-vivo studies. 
 
With the calculated half-life of metribolone, the clearance could be further 
studied in-vivo where its biological half-life can be investigated. The identity 
of the postulated metabolite, 16-hydroxy metribolone, could be further 
elucidated using commercially available standards. 
 
5.2.2 Non-targeted approach 
 
The limitations of the current global equine plasma profiling model might be 
potentially overcome by increasing the sample size and exploring other 





coupled to TOFMS, LC/MS, CE/MS or NMR. The samples could be analyzed 
using instruments like GC x GC/TOFMS to provide a higher metabolic space 
coverage with enhanced detection limit. This analytical method could increase 
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